Bicycle Therapeutics (BCYC) Liabilities and Shareholders Equity (2018 - 2026)

Bicycle Therapeutics has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $652.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 26.19% year-over-year to $652.4 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 billion (down 23.85% YoY), and the FY2025 full-year result was $717.6 million, down 25.01% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $652.4 million, down from $717.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.1 billion in Q2 2024, with the low at $410.6 million in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $662.2 million across 5 years, with a median of $638.7 million in 2023.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 132.81% — and 2026, when it declined 26.19%.
• Bicycle Therapeutics' Liabilities and Shareholders Equity stood at $410.6 million in 2022, then soared by 44.99% to $595.3 million in 2023, then jumped by 60.73% to $956.9 million in 2024, then declined by 25.01% to $717.6 million in 2025, then fell by 9.09% to $652.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $652.4 million (Q1 2026), $717.6 million (Q4 2025), and $764.0 million (Q3 2025), per Business Quant data.